Fig. 7

Rho GTPase-related gene signature can predict efficacy of immunotherapy. A Scatterplots displaying the correlation of RGPRG score and tumor mutation burden. B The relationship of Exclusion between high- and low-RGPRG score HCC patients. C The relationship of Dysfunction between high- and low-RGPRG score HCC patients. D The relationship of TIDE between high- and low-RGPRG score HCC patients. E, I The boxplot shows the correlation of PDL1 expression and RGPRG score groups in IMvigor210, and the differences in PD1 expression between RGPRG score groups in GSE78220. F, J Distinct clinical outcomes of anti-PDL1 and PD-1 blockade immunotherapy between high- and low-RGPRG score groups in IMvigor210 and GSE78220. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. G, K The proportion of distinct clinical outcomes between high- and low-RGPRG score groups in IMvigor210 and GSE78220. H, L Kaplan–Meier survival curve showing the survival difference between high- and low-RGPRG score groups in IMvigor210 and GSE78220